PATH Meningitis Vaccine Gets $100M

5/11/11Follow @xconomy

The GAVI Alliance, the Geneva, Switzerland-based global health organization, said today it has committed $100 million to support the use of a meningitis vaccine developed by Seattle-based PATH. The vaccine, MenAfriVac, was developed through a $70 million grant from the Bill & Melinda Gates Foundation, and a 10-year development effort. It has been widely used in recent months in Burkina Faso, and now GAVI said it wants to further disseminate it in Cameroon, Chad, and Nigeria. For more of the background on the meningitis vaccine effort, check this feature I wrote back in December.

By posting a comment, you agree to our terms and conditions.